Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 3
1982 8
1983 7
1984 6
1985 15
1986 12
1987 14
1988 18
1989 25
1990 24
1991 21
1992 36
1993 30
1994 24
1995 39
1996 27
1997 33
1998 34
1999 33
2000 27
2001 29
2002 24
2003 28
2004 29
2005 30
2006 26
2007 31
2008 17
2009 17
2010 9
2011 23
2012 24
2013 19
2014 16
2015 18
2016 13
2017 19
2018 8
2019 11
2020 7
2021 7
2022 11
2023 9
2024 10
2025 13
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

854 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial.
Keij FM, Kornelisse RF, Hartwig NG, van der Sluijs-Bens J, van Beek RHT, van Driel A, van Rooij LGM, van Dalen-Vink I, Driessen GJA, Kenter S, von Lindern JS, Eijkemans M, Stam-Stigter GM, Qi H, van den Berg MM, Baartmans MGA, van der Meer-Kappelle LH, Meijssen CB, Norbruis OF, Heidema J, van Rossem MC, den Butter PCP, Allegaert K, Reiss IKM, Tramper-Stranders GA. Keij FM, et al. Lancet Child Adolesc Health. 2022 Nov;6(11):799-809. doi: 10.1016/S2352-4642(22)00245-0. Epub 2022 Sep 9. Lancet Child Adolesc Health. 2022. PMID: 36088952 Clinical Trial.
A margin of 3% was deemed to indicate non-inferiority, thus if the reinfection rate in the oral amoxicillin-clavulanic acid group was less than 3% higher than that in the intravenous antibiotic group the null hypothesis would be rejected. ...In the intention- …
A margin of 3% was deemed to indicate non-inferiority, thus if the reinfection rate in the oral amoxicillin-clavulanic acid …
Identifying Children Likely to Benefit From Antibiotics for Acute Sinusitis: A Randomized Clinical Trial.
Shaikh N, Hoberman A, Shope TR, Jeong JH, Kurs-Lasky M, Martin JM, Bhatnagar S, Muniz GB, Block SL, Andrasko M, Lee MC, Rajakumar K, Wald ER. Shaikh N, et al. JAMA. 2023 Jul 25;330(4):349-358. doi: 10.1001/jama.2023.10854. JAMA. 2023. PMID: 37490085 Free PMC article. Clinical Trial.
The trial was conducted between February 2016 and April 2022 at primary care offices affiliated with 6 US institutions and was designed to evaluate whether symptom burden differed in subgroups defined by nasopharyngeal Streptococcus pneumoniae, Haemophilus influenzae, or Moraxell …
The trial was conducted between February 2016 and April 2022 at primary care offices affiliated with 6 US institutions and was designed to e …
Short Oral Antibiotic Therapy for Pediatric Febrile Urinary Tract Infections: A Randomized Trial.
Montini G, Tessitore A, Console K, Ronfani L, Barbi E, Pennesi M; STOP Trial Group. Montini G, et al. Pediatrics. 2024 Jan 1;153(1):e2023062598. doi: 10.1542/peds.2023-062598. Pediatrics. 2024. PMID: 38146260 Free article. Clinical Trial.
Secondary end points were the difference in prevalence of clinical recovery, adverse drug-related events, and resistance to amoxicillin-clavulanic acid and/or to other antibiotics when a recurrent infection occurred. ...CONCLUSIONS: This study demonstrates th …
Secondary end points were the difference in prevalence of clinical recovery, adverse drug-related events, and resistance to amoxicillin …
Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. ORACLE Collaborative Group.
Kenyon SL, Taylor DJ, Tarnow-Mordi W; ORACLE Collaborative Group. Kenyon SL, et al. Lancet. 2001 Mar 31;357(9261):979-88. doi: 10.1016/s0140-6736(00)04233-1. Lancet. 2001. PMID: 11293640 Clinical Trial.
METHODS: 4826 women with pPROM were randomly assigned 250 mg erythromycin (n=1197), 325 mg co-amoxiclav (250 mg amoxicillin plus 125 mg clavulanic acid; n=1212), both (n=1192), or placebo (n=1225) four times daily for 10 days or until delivery. ...
METHODS: 4826 women with pPROM were randomly assigned 250 mg erythromycin (n=1197), 325 mg co-amoxiclav (250 mg amoxicillin plus 125 …
Exploratory Pilot Studies to Demonstrate Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics.
Merenstein D, Tan T, Herbin Smith K. Merenstein D, et al. Ann Fam Med. 2024 Nov 1;21(Suppl 3):4766. doi: 10.1370/afm.22.s1.4766. Ann Fam Med. 2024. PMID: 38271205 Free PMC article. Clinical Trial.
Objectives: The primary aim is to determine the ability of BB-12 to impact antibiotic-induced reduction in short chain fatty acid concentration (SCFA), as reflected by the levels of acetate on day 14. Secondarily to determine the ability of BB-12 to impact antibiotic-induc …
Objectives: The primary aim is to determine the ability of BB-12 to impact antibiotic-induced reduction in short chain fatty acid con …
Amoxicillin-clavulanic acid (Augmentin).
[No authors listed] [No authors listed] Med Lett Drugs Ther. 1984 Nov 9;26(674):99-100. Med Lett Drugs Ther. 1984. PMID: 6387417 Clinical Trial. No abstract available.
Prulifloxacin.
Keam SJ, Perry CM. Keam SJ, et al. Drugs. 2004;64(19):2221-34; discussion 2235-6. doi: 10.2165/00003495-200464190-00005. Drugs. 2004. PMID: 15456336 Clinical Trial.
In well designed clinical trials, good clinical and bacteriological efficacy (similar to that of ciprofloxacin, amoxicillin/clavulanic acid or pefloxacin) was seen with prulifloxacin 600 mg once daily for 10 days in patients with acute exacerbations of chroni …
In well designed clinical trials, good clinical and bacteriological efficacy (similar to that of ciprofloxacin, amoxicillin/clavul …
The treatment of chancroid.
Schmid GP. Schmid GP. JAMA. 1986 Apr 4;255(13):1757-62. JAMA. 1986. PMID: 3512872 Review.
Sulfamethoxazole and trimethoprim (800 mg/160 mg orally twice a day for seven days), ceftriaxone (250 mg intramuscularly one time), and amoxicillin/clavulanic acid (500 mg/125 mg orally three times a day for seven days) are also efficacious. There is, however …
Sulfamethoxazole and trimethoprim (800 mg/160 mg orally twice a day for seven days), ceftriaxone (250 mg intramuscularly one time), and a …
Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Todd PA, Benfield P. Todd PA, et al. Drugs. 1990 Feb;39(2):264-307. doi: 10.2165/00003495-199039020-00008. Drugs. 1990. PMID: 2184003 Review.
Clavulanic acid enhances the antibacterial spectrum of amoxicillin by rendering most beta-lactamase-producing isolates susceptible to the drug. ...Thus, in general practice environments where beta-lactamase production has restricted the effectiveness of am …
Clavulanic acid enhances the antibacterial spectrum of amoxicillin by rendering most beta-lactamase-producing isolates …
Purulent nasal discharge.
Wald ER. Wald ER. Pediatr Infect Dis J. 1991 Apr;10(4):329-33. doi: 10.1097/00006454-199104000-00013. Pediatr Infect Dis J. 1991. PMID: 2062631 Clinical Trial.
854 results